key: cord-0311888-r9gft09q
authors: Koeppen, Katja; Hampton, Thomas H.; Gerber, Scott A.; Goo, Young Ah; Cho, Byoung-Kyu; Vermilyea, Danielle M.; Hogan, Deborah A.; Stanton, Bruce A.
title: An rRNA fragment in extracellular vesicles secreted by human airway epithelial cells increases the fluoroquinolone sensitivity of P. aeruginosa
date: 2022-04-21
journal: bioRxiv
DOI: 10.1101/2022.04.19.488721
sha: 740196f7ef3defa0261d0e3762c8a7cb45b671cb
doc_id: 311888
cord_uid: r9gft09q

Lung infection by antibiotic resistant strains of Pseudomonas aeruginosa is a well-known concern for immunocompromised hosts including people with lung diseases such as cystic fibrosis. We have previously demonstrated that extracellular vesicles (EVs) secreted by primary human airway epithelial cells (AEC) deliver miRNA let-7b-5p to P. aeruginosa where it suppresses biofilm formation and increases sensitivity to beta-lactam antibiotics. In this study we used RNA-seq to characterize the small RNA (sRNA) content of EVs secreted by AEC and demonstrate transfer of multiple distinct RNA fragments from EVs to P. aeruginosa. Bioinformatic predictions reveal that several sRNAs may target all three subunits of the fluoroquinolone efflux pump MexHI-OpmD, an effect predicted to increase antibiotic sensitivity to fluoroquinolone antibiotics. Exposure of P. aeruginosa to EVs resulted in a significant reduction in the protein levels of MexH (−48%), MexI (−50%) and OpmD (−35%). Moreover, EVs reduced planktonic growth of P. aeruginosa in the presence of the fluoroquinolone antibiotic ciprofloxacin by 20%. A mexGHI-opmD deletion mutant of P. aeruginosa phenocopied this increased sensitivity to ciprofloxacin. Finally, we found that a fragment of an 18S rRNA external transcribed spacer that was transferred to P. aeruginosa by EVs was sufficient to reduce planktonic growth of P. aeruginosa in the presence of ciprofloxacin, to reduce the minimum inhibitory concentration (MIC) of P. aeruginosa for ciprofloxacin by over 50%, and to significantly reduce protein levels of MexH and OpmD. In conclusion, an rRNA fragment secreted by AEC in EVs increases the ciprofloxacin sensitivity of P. aeruginosa by targeting and down-regulating the fluoroquinolone efflux pump MexHI-OpmD. A combination of rRNA fragments and ciprofloxacin packaged in nanoparticles or EVs may benefit patients with antibiotic-resistant P. aeruginosa infections. Author Summary According to the World Health Organization and the U.S. Centers for Disease Control and Prevention the development of antibiotic resistant strains of bacteria, including Pseudomonas aeruginosa, are a significant global threat to human health. Thus, development of new approaches to eliminate antibiotic resistant infections is required. In this study, we report that lung epithelial cells secrete extracellular vesicles (EVs) that fuse with and deliver small rRNAs to P. aeruginosa, and that the rRNAs increase the sensitivity of P. aeruginosa to the antibiotic ciprofloxacin by reducing protein levels of the drug efflux pump MexHI-OpmD. We identified one rRNA fragment that by itself significantly reduced the protein levels of MexH and OpmD and increased the ability of ciprofloxacin to kill P. aeruginosa. We propose that developing synthetic vesicles containing a combination of the rRNA that inhibits antibiotic efflux pumps and ciprofloxacin would benefit patients with antibiotic resistant P. aeruginosa infections.

Pseudomonas aeruginosa is an opportunistic bacterial pathogen that can cause chronic 66 infections in immunocompromised hosts, leading to increased morbidity and mortality in 67 individuals with cystic fibrosis (CF), chronic obstructive pulmonary disease (COPD), ventilator-68 associated pneumonia and burn wounds (1) . P. aeruginosa is also emerging as a pathogen that 69 commonly co-infects and exacerbates COVID-19 infections (2) (3) (4) (5) . The rise of difficult-to-70 eradicate, antibiotic resistant strains of P. aeruginosa is posing treatment challenges and 71 increasingly becoming a concern in healthcare settings (6) (7) (8) (9) . Multidrug-resistant strains of P. (45) (46) (47) . Recently, we provided the first direct evidence that a miRNA, let-7b-5p, in EVs 108 secreted by human airway epithelial cells, is transferred to P. aeruginosa, where it increases 109 beta-lactam antibiotic sensitivity and decreases biofilm formation by reducing the abundance of 110 the beta-lactamase AmpC and several proteins required for biofilm formation (19). Here, we 111 report that human EVs also reduce the abundance of all three subunits of the fluoroquinolone In a previous study we demonstrated that EVs secreted by AEC increased the sensitivity of P. 120 aeruginosa to beta lactam antibiotics by delivering the miRNA let-7b to P. aeruginosa (19) . To 121 test the hypothesis that EVs may also alter the sensitivity to other antibiotics typically used to 122 treat infections by P. aeruginosa (48) , we examined the ability of EVs to alter the sensitivity of P. 123 aeruginosa to the fluoroquinolone antibiotic ciprofloxacin. To that end, the planktonic growth of 124 P. aeruginosa strain PA14 as well as the mucoid P. aeruginosa CF clinical isolate SMC1585 125 (49) were measured in the presence and absence of EVs and in the presence and absence of 126 eight different concentrations of ciprofloxacin to determine the minimal inhibitory concentration 127 (MIC). EVs alone had no significant effect on planktonic growth of PA14 in the absence of 128 ciprofloxacin ( Fig 1A) but reduced the MIC of ciprofloxacin by 25% (Fig 1B) . EVs reduced 129 planktonic growth of PA14 in the presence of 0.02 µg/ml ciprofloxacin (corresponding to about 130 one third of the MIC) by 26%, compared to 0.02 µg/ml ciprofloxacin alone ( Fig 1C) . Likewise,

EVs alone had no significant effect on planktonic growth of clinical isolate SMC1585 in the 132 absence of ciprofloxacin ( Fig 1D) but reduced the MIC of ciprofloxacin by 48% ( Fig 1E) . EVs 133 reduced planktonic growth of SMC1585 in the presence of 0.02 µg/ml ciprofloxacin by 27%, 134 compared to 0.02 µg/ml ciprofloxacin alone (Fig 1F) . Full 20-hour growth curves for EV-exposed 135 and vehicle exposed PA14 and SMC1585 in the presence and absence of 0.02 µg/ml 136 ciprofloxacin are shown in S1 Fig To begin to elucidate the mechanism whereby EVs increased the sensitivity of P. aeruginosa to 145 ciprofloxacin we analyzed the proteome of P. aeruginosa that had been exposed to EVs or 146 vehicle control. EVs reduced the protein levels of all three subunits of the fluoroquinolone efflux 7 pump MexHI-OpmD (Table 1) 

We previously found that EVs secreted by AEC deliver the miRNA let-7b-5p to P. aeruginosa,

where it reduced biofilm formation and increased sensitivity to beta-lactam antibiotics by

targeting key genes involved in biofilm formation and beta-lactam resistance (19). However, let- Table) .

Collectively, these 909 unique sequences accounted for 60% of total reads detected in all 3 182 replicate samples. The sequences with the highest total count (listed at the top of S2 Table) 183 include many tRNA and lncRNA fragments. 

Transfer of EV sRNAs to P. aeruginosa 194 We previously described the transfer of miRNAs secreted in AEC EVs to P. aeruginosa (19). To 195 assess the transfer of other sRNAs besides miRNAs to P. aeruginosa, we re-analyzed RNA-seq 196 data of EV-exposed P. aeruginosa and unexposed controls (GSE174710). We generated count 197 tables of unique sequences from trimmed reads for individual samples -three unexposed 198 controls and three samples of P. aeruginosa exposed to EVs secreted by different AEC donors.

Reads were filtered to include only sequences with a length of at least 20 nucleotides that were 200 detected in all three EV-exposed P. aeruginosa samples and none of the unexposed control Table 3 were detected in EV-205 exposed P. aeruginosa, but not in any of the unexposed control samples, suggesting that they 206 are delivered to P. aeruginosa by EVs. Subsequently, we used IntaRNA to predict target genes 207 of these 15 human EV sRNAs in P. aeruginosa. 

18S rRNA external transcribed spacer (highlighted in bold font in Table 3 ). As described next, of 

The finding that AEC EVs contain rRNA fragments is consistent with prior characterizations of 277 the sRNA content of EVs secreted by airway epithelial cells (40, 41) . It has been previously 278 described that rRNA fragments are produced in a controlled manner that is population-, sex- 

We found that some, but not all, of the most abundant sequences in EVs can be detected in P.

aeruginosa following EV exposure. However, some human EV sRNA sequences detected in 309 EV-exposed P. aeruginosa are not among the most abundant EV sequences, suggesting 310 differential stability in P. aeruginosa. While RNA contained within EVs is protected from 311 degradation by extracellular RNases, once the EV RNA cargo is delivered to P. aeruginosa,

RNA that is not protected by binding to protein or P. aeruginosa mRNA targets may be more 313 prone to degradation, explaining the discrepancy between abundance in EVs compared to the 314 abundance after delivery to P. aeruginosa for some of the sRNAs.

One limitation of our study is that we did not assess other AEC EV cargo such as DNA, protein, 316 lipids, or metabolites, which could contribute to EV induced sensitivity to ciprofloxacin. However, 

To assess whether EV sRNA targeting of efflux pumps is limited to P. aeruginosa or extends to 355 efflux pump orthologs in other common lung pathogens we utilized IntaRNA to predict targeting 356 of Burkholderia cenocepacia (which has orthologs for mexH, mexI and opmD) and

Staphylococcus aureus (which has an ortholog for mexI). Our candidate rRNA spacer fragment 358 is predicted to target orthologs of mexI and opmD in Burkholderia cenocepacia, suggesting that 359 AEC EV sRNAs are likely to affect other lung pathogens beyond P. aeruginosa and warrant 360 future analysis beyond the scope of the current study.

In summary, our study provides the first evidence for transfer of lncRNA, tRNA and rRNA 362 fragments from eukaryotic EVs to a prokaryote and provides direct evidence for regulation of the 

(A) 20-hour planktonic growth curves (OD600) of PA14 exposed to EVs or vehicle control (ctrl) 566 in the absence of ciprofloxacin. There was no significant difference between the growth curves 567 for the last 4 hours of growth. (B) 20-hour planktonic growth curves (OD600) of PA14 exposed 568 to 0.02 µg/ml ciprofloxacin and EVs or 0.02 µg/ml ciprofloxacin and vehicle control (ctrl). There 569 was a significant difference between the growth curves for the last 4 hours of growth. (C) 20-570 hour planktonic growth curves (OD600) of clinical isolate SMC1585 exposed to EVs or vehicle 571 control (ctrl) in the absence of ciprofloxacin. There was no significant difference between the 572 growth curves for the last 4 hours of growth. (D) 20-hour planktonic growth curves (OD600) of 573 clinical isolate SMC1585 exposed to 0.02 µg/ml ciprofloxacin and EVs or 0.02 µg/ml 574 ciprofloxacin and vehicle control (ctrl). There was a significant difference between the growth 575 curves for the last 4 hours of growth. Each data point shows the mean +/-SEM of EVs isolated 576 from four AEC donors (or matching controls), averaged across three technical replicates.

Statistical significance was determined using permutation tests. * P < 0.05. 599 600 S1 Table. Proteomics data of EV-exposed P. aeruginosa and unexposed controls. 

It's Not Easy Being Green: A Narrative Review on the 618

Therapeutic Prospects of Multidrug-Resistant Pseudomonas 619 aeruginosa. Antibiotics (Basel)

State-of-the-art review of 622 secondary pulmonary infections in patients with COVID-19 pneumonia

Incidence and 625 Prognosis of Ventilator-Associated Pneumonia in Critically Ill Patients

Multicenter Study

Persistent Bacterial Coinfection of a 629 COVID-19 Patient Caused by a Genetically Adapted Pseudomonas aeruginosa Chronic 630

Bacterial and fungal co-infections 632 among COVID-19 patients in intensive care unit. Microbes Infect

Antimicrobial resistance: Concerns of healthcare providers and people with CF

The problems of antibiotic 640 resistance in cystic fibrosis and solutions. Expert Review of Respiratory Medicine

Characterization of 643 antibiotic resistance profiles in Pseudomonas aeruginosa isolates from burn patients

Clinical 646 characteristics and risk factors for the isolation of multi-drug-resistant Gram-negative 647 bacteria from critically ill patients with COVID-19

A Novel 650 Mechanism of Host-Pathogen Interaction through sRNA in Bacterial Outer Membrane 651 Vesicles

Uropathogenic Escherichia coli Releases Extracellular Vesicles That Are Associated with 654 RNA

Secretable Small RNAs via Outer Membrane 656 Vesicles in Periodontal Pathogens

Small Luggage for a Long Journey: Transfer of Vesicle-Enclosed 658

Microbe-Host Communication by Small RNAs in Extracellular Vesicles: Vehicles 662 for Transkingdom RNA Transportation

Extracellular Vesicles EV-RNA Communication as a Mechanism for Host-Pathogen 665

Bacterial RNA in extracellular vesicles: A new regulator of 667 host-pathogen interactions? Biochimica et Biophysica Acta (BBA) -Gene Regulatory 668 Mechanisms

sncRNAs packaged by Helicobacter 670 pylori outer membrane vesicles attenuate IL-8 secretion in human cells

Let-7b-5p in 673 vesicles secreted by human airway cells reduces biofilm formation and increases antibiotic 674 sensitivity of P. aeruginosa

Exosomes in 676 human semen carry a distinctive repertoire of small non-coding RNAs with potential 677 regulatory functions

Selective Export into Extracellular Vesicles and 679 Function of tRNA Fragments during T Cell Activation

The Long and Short of It: The Emerging Roles of Non-Coding 682 RNA in Small Extracellular Vesicles

Hints of tRNA-Derived Small 684

RNAs Role in RNA Silencing Mechanisms. Genes (Basel)

A novel class of small RNAs: tRNA-derived 686 RNA fragments (tRFs). Genes Dev

Meta-analysis of tRNA derived RNA fragments 688 reveals that they are evolutionarily conserved and associate with AGO proteins to recognize 689 specific RNA targets

Avcilar-Kucukgoze I, Kashina A. Hijacking tRNAs From Translation: Regulatory 695 Functions of tRNAs in Mammalian Cell Physiology

tRNA fragments in human health and disease

Action mechanisms and research methods of 699 tRNA-derived small RNAs. Signal Transduction and Targeted Therapy

Small RNA 702 Transcriptomes of Two Types of Exosomes in Human Whole Saliva Determined by Next 703

Vesiculated Long Non-Coding RNAs: Offshore Packages Deciphering 705

Trans-Regulation between Cells, Cancer Progression and Resistance to Therapies. Non-706 Coding RNA

Transfer RNA-Derived Fragments, the Underappreciated Regulatory 708

Extracellular Vesicles and Host-Pathogen Interactions: A Review of Inter-710

Kingdom Signaling by Small Noncoding RNA. Genes (Basel)

Extracellular vesicles in lung 712 microenvironment and pathogenesis

Extracellular Vesicles: New Players in 715 Lung Immunity

Exosomes in 717 immunoregulation of chronic lung diseases

Extracellular vesicles in 719 lung health, disease, and therapy

Bronchial epithelial cell extracellular 722 vesicles ameliorate epithelial-mesenchymal transition in COPD pathogenesis by alleviating 723 M2 macrophage polarization

MiRNA Expression Profile in the Airways Is Altered during Pulmonary 727 Exacerbation in Children with Cystic Fibrosis-A Preliminary Report

Respiratory Syncytial 731 Virus Infection Changes Cargo Composition of Exosome Released from Airway Epithelial 732

Cigarette Smoke Condensate Exposure 735

Changes RNA Content of Extracellular Vesicles Released from Small Airway Epithelial 736 Cells. Cells

738 Pulmonary microRNA profiling: implications in upper lobe predominant lung disease

Molecular techniques for 742 respiratory diseases: MicroRNA and extracellular vesicles

Exosomal miRNAs in Lung 745 Diseases: From Biologic Function to Therapeutic Targets

The Host Shapes the Gut 749 Microbiota via Fecal MicroRNA

Oral Administration 751 of miR-30d from Feces of MS Patients Suppresses MS-like Symptoms in Mice by 752

Expanding Akkermansia muciniphila. Cell Host Microbe

MicroRNAs Shape the Gut Microbiota

consensus working group. 756 Inhaled medication and inhalation devices for lung disease in patients with cystic fibrosis: 757 A European consensus

Combination of hypothiocyanite and 759 lactoferrin (ALX-109) enhances the ability of tobramycin and aztreonam to eliminate 760 Pseudomonas aeruginosa biofilms growing on cystic fibrosis airway epithelial cells

IntaRNA: efficient prediction of bacterial sRNA targets 763 incorporating target site accessibility and seed regions

IntaRNA 2.0: enhanced and customizable prediction of 766 RNA-RNA interactions

Cherlin T. Ribosomal RNA fragmentation into short RNAs (rRFs) is modulated in a sex-768 and population of origin-specific manner

Small Non-Coding RNAs Derived From Eukaryotic 770

Age-Related Argonaute Loading of Ribosomal RNA Fragments. 772 MIRNA

Computational meta-analysis of ribosomal RNA fragments: potential 774 targets and interaction mechanisms

Two featured series of rRNA-derived 776 RNA fragments (rRFs) constitute a novel class of small

Profiling and Identification of Small 779 rDNA-Derived RNAs and Their Potential Biological Functions

An endogenous 782 small interfering RNA pathway in Drosophila

qiRNA, a new 784 type of small interfering RNA induced by DNA damage

Self-circularizing 5′-ETS RNAs 787 accumulate along with unprocessed pre ribosomal RNAs in growth-stressed Entamoeba 788 histolytica. Sci Rep

Kinetic control of quorum 790 sensing in Pseudomonas aeruginosa by multidrug efflux pumps

Antibacterial-Resistant Pseudomonas aeruginosa : 793 Clinical Impact and Complex Regulation of Chromosomally Encoded Resistance 794 Mechanisms

Mechanisms of ciprofloxacin resistance in 796 Pseudomonas aeruginosa: new approaches to an old problem

Phospho RNA seq: a modified small RNA seq method that reveals circulating mRNA 800 and lncRNA fragments as potential biomarkers in human plasma

EVs from BALF-Mediators 804 of Inflammation and Potential Biomarkers in Lung Diseases

Human nasal and tracheo-bronchial respiratory epithelial cell 807 culture

Derived Macrophages Have an Attenuated Response to Extracellular Vesicles Secreted by 810 Airway Epithelial Cells

Saccharomyces 812 cerevisiae-based molecular tool kit for manipulation of genes from gram-negative bacteria

Susceptibility testing: accurate and reproducible minimum 815 inhibitory concentration (MIC) and non-inhibitory concentration (NIC) values

Absence of Membrane Phosphatidylcholine Does Not 818

Affect Virulence and Stress Tolerance Phenotypes in the Opportunistic Pathogen 819 Pseudomonas aeruginosa

MicroRNAs Detected in Extracellular Vesicles From Bronchoalveolar Lavage Fluid of 823 Patients With Influenza Virus-Induced Acute Respiratory Distress Syndrome. The Journal 824 of Infectious Diseases

QPROT: statistical method for 826 testing differential expression using protein-level intensity data in label-free quantitative 827 proteomics

The 829 ProteomeXchange consortium in 2020: enabling "big data" approaches in proteomics. 830

Assembling the 832 Community-Scale Discoverable Human Proteome

The PRIDE database resources in 2022: a hub for mass spectrometry-based 835 proteomics evidences

fastp: an ultra-fast all-in-one FASTQ preprocessor

architecture and applications

rentrez: An R package for the NCBI eUtils API

Core Team. R: A language and environment for statistical computing

Austria: R Foundation for Statistical Computing

Wound healing response is a major contributor to the severity of cutaneous leishmaniasis in 847 the ear model of infection

Leishmaniasis 849 host response loci (lmr1-3) modify disease severity through a Th1/Th2-independent 850 pathway